Mavacamten Safety and Efficacy in a Heart Transplant Patient Exhibiting Obstructive Hypertrophic Cardiomyopathy Phenotype
Hypertrophic cardiomyopathy is the most common inherited cardiac disease, exhibiting diverse phenotypes. Obstructive hypertrophic cardiomyopathy occurs in about two-thirds of cases and carries a worse prognosis. Mavacamten use in heart transplant recipients is limited. This paper reports a recipient who developed severe symptomatic obstructive hypertrophic cardiomyopathy phenotype/phenocopy and was initiated on mavacamten.
Authors
- Asad Ghafoor
- M. Fuad Jan (ORCID: https://orcid.org/0000-0001-5072-710X)
- Arshad Jahangir (ORCID: https://orcid.org/0000-0001-5582-3336)
- Muddasir Ashraf (ORCID: https://orcid.org/0000-0001-9710-7610)
- A. Jamil Tajik (ORCID: https://orcid.org/0000-0002-4784-1275)
- Patrycja Galazka (ORCID: https://orcid.org/0000-0002-5952-7996)
- Zaid Abood (ORCID: https://orcid.org/0009-0005-8164-9024)
- Matthew Peters
- Amanda Misicka
Institutions
- Aurora Health Care (US)
- Aurora St. Luke's Medical Center (US)
- University of Wisconsin–Milwaukee (US)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1016/j.jaccas.2024.102454
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00